Modafinil

Contraindications

Modafinil is contraindicated (should not be used) during pregnancy and 2 months before getting pregnant. Women who take modafinil should not become pregnant, and, additionally, should be aware that modafinil reduces effectiveness of hormonal contraceptives, increasing chances of getting pregnant. Modafinil therapy during pregnancy increases the risk of birth defects, such as with congenital torticollis (twisted neck), hypospadias (a urethral abnormality), and congenital heart defects.

Modafinil is contraindicated for individuals with known hypersensitivity (allergic reaction) to either modafinil or armodafinil.

Modafinil is also contraindicated in certain cardiac conditions, including uncontrolled moderate to severe hypertension, arrhythmia, cor pulmonale, and in cases with signs of CNS stimulant-induced mitral valve prolapse or left ventricular hypertrophy. These contraindications arise because modafinil elicits sympathomedullary activation, producing notable increases in heart rate and blood pressure that can worsen pre-existing cardiovascular conditions.

Modafinil is also contraindicated in people with galactose intolerance, lactase deficiency, or glucose-galactose malabsorption (inherited conditions affecting the digestion of certain sugars, relevant because modafinil tablets contain lactose monohydrate as an inactive ingredient).

Adverse effects

Modafinil is generally well-tolerated but can have potential risks and side effects. Common adverse effects of modafinil, experienced by less than 10% of users, include headaches, nausea, and reduced appetite. Anxiety, insomnia, dizziness, diarrhea, and rhinitis (nasal congestion) are also reported in 5%–10% of users. Psychiatric reactions have occurred in individuals with and without a preexisting psychiatric history. Urinary retention (difficulty emptying the bladder) and paresthesia (tingling or numbness) have also been reported.

Modafinil has been found to have sympathomimetic effects, including increasing heart rate, blood pressure, and orthostatic elevations in norepinephrine levels. Modafinil can cause a slight increase in aminotransferase enzymes, indicative of liver function, but there is no evidence of serious liver damage when levels are within reference ranges. Case reports of modafinil-associated hypersexuality and spontaneous orgasms and ejaculations exist.

Rare but serious adverse effects include severe skin rashes and allergy-related symptoms. Between December 1998 and January 2007, the US Food and Drug Administration (FDA) received reports of six cases of severe cutaneous adverse reactions, including erythema multiforme (target-shaped skin lesions), Stevens–Johnson syndrome, toxic epidermal necrolysis (widespread skin peeling), and DRESS syndrome (a drug reaction involving rash and organ inflammation). The FDA has issued alerts regarding these risks and also noted reports of angioedema and multi-organ hypersensitivity reactions in postmarketing surveillance. In 2007, the FDA required Cephalon, the manufacturer of Provigil, to modify the Provigil leaflet to include warnings about these serious conditions. The long-term safety and effectiveness of modafinil have not been conclusively established.

The FDA does not endorse modafinil for children's medical conditions due to an increased risk of rare but serious dermatological toxicity, manifested as Stevens–Johnson syndrome which is a type of severe skin reaction. However, in Europe, modafinil may be prescribed for treating narcolepsy in children.

Tolerance

Clinical research has not demonstrated drug tolerance, a reduction in wakefulness-promoting and anti-fatigue effects, as a common outcome, even with therapeutic use extending up to 40 weeks. However, long-term use can lead to tolerance in some individuals, necessitating higher doses to maintain efficacy. People with current or past substance addictions and those with a family history of addiction are at higher risk. The underlying mechanisms, which may involve dopamine and norepinephrine pathways, are not fully understood. Tolerance appears more likely with off-label use for cognitive enhancement than with therapeutic use for narcolepsy, where effectiveness does not usually diminish with prolonged treatment.

Addiction and dependence

Although classified as a central nervous system (CNS) stimulant, the addiction and dependence liabilities of modafinil are considered low. The exact mechanisms of action of modafinil are not known, and its pharmacological profile differs from that of the classical stimulants such as cocaine or amphetamine. Although modafinil shares biochemical mechanisms with stimulant drugs, it is less likely to have mood-elevating properties. The similarities in effects with caffeine are not clearly established. Unlike other stimulants, modafinil does not induce a strong subjective feeling of pleasure or reward or euphoria, which contributes to its lower abuse potential. Albeit to a lower degree than classical stimulants, modafinil still can produce psychoactive, euphoric, and subjective effects typical for abused stimulants.

Despite initial assessments of low abuse potential, some evidence indicates modafinil acts on the same neurobiological mechanisms as other addictive stimulants, which is a reason for caution when prescribing. Modafinil scores lower than amphetamine on standardized abuse-potential assessments, suggesting reduced propensity for abuse.

The US Drug Enforcement Administration has classified modafinil as a Schedule IV controlled substance; the medicine is recognized for having valid medical uses with low addiction potential. The International Narcotics Control Board does not classify it as a narcotic or a psychotropic substance.

Overdose

An overdose of modafinil can lead to a range of symptoms and complications. Psychiatric symptoms may include psychosis, mania, hallucinations, and suicidal ideation, which can occur even in individuals without a history of mental illness and may persist after discontinuation of modafinil. Neurological complications, such as seizures, tremors, dystonia (involuntary muscle contractions), and dyskinesia (uncontrolled movements), may arise from modafinil's interaction with various neurotransmitter systems.

Allergic reactions such as rash, angioedema (swelling beneath the skin), anaphylaxis (a severe whole-body allergic reaction), and Stevens–Johnson syndrome (a serious skin and mucous membrane disorder) may rarely be triggered by an immunological response to modafinil or its metabolites. Cardiovascular complications like hypertension, tachycardia (rapid heart rate), chest pain, and arrhythmias may also occur because modafinil stimulates the sympathetic nervous system.

In animal studies, the median lethal dose (LD₅₀) of modafinil varies among species and depends on the route of administration. In mice and rats, the LD₅₀ is approximately 1250 mg/kg if administered via an injection, but the oral LD₅₀ for rats is 3400 mg/kg. The LD₅₀ value for humans have not been established. Human clinical trials have involved total daily doses up to 1200 mg/d for 7–21 days. Acute one-time total overdoses up to 4500 mg have not been life-threatening but resulted in symptoms like agitation, insomnia, tremor, palpitations, and gastrointestinal disturbances.

The management of modafinil overdose involves supportive care, monitoring of vital signs, and treatment of specific complications. In cases of recent consumption, activated charcoal, gastric lavage (stomach pumping), or hemodialysis (blood filtering) may be used. There is no specific antidote for modafinil overdose. The main way to deal with modafinil overdose is supportive care, which includes sedating the patient and stabilizing their blood pressure, and muscle activity in case of manifestations such as agitation or tremor.

Interactions

Some of the drugs that frequently interact with modafinil include aripiprazole (an antipsychotic), amphetamine (including its enantiomers and salts; stimulants), and others.

Modafinil is a weak to moderate inducer of CYP3A4 and a weak inhibitor of CYP2C19, enzymes of the cytochrome P450 system. Modafinil also induces or inhibits other cytochrome P450 enzymes. One in vitro study predicts that modafinil may induce the cytochrome P450 enzymes CYP1A2, CYP3A4, and CYP2B6, as well as may inhibit CYP2C9 and CYP2C19. However, other in-vitro work has shown no significant inhibition of CYP2C9. Modafinil may induce P-glycoprotein, which may affect drugs transported by P-glycoprotein, such as digoxin.

In clinical use, modafinil affects the pharmacodynamics of drugs metabolized by CYP3A4 and other cytochrome P450 enzymes, with these interactions observed in patients. For instance, CYP3A4 induction by modafinil can reduce plasma concentrations of opioids such as methadone, hydrocodone, oxycodone, and fentanyl, potentially causing reduced efficacy or withdrawal symptoms. Modafinil also affects steroid hormones, including estradiol, progesterone, and cortisol, and can reduce the effectiveness of hormonal contraceptives for up to a month after discontinuation. Since modafinil induces the activity of the CYP3A4 enzyme involved in cortisol clearance, modafinil may reduce the bioavailability of hydrocortisone. Therefore, it may be necessary to adjust the steroid substitution dose in people receiving modafinil, which is a CYP3A4-metabolism-inducing drug.

Hypertensive crises have been reported when armodafinil (one of modafinil's enantiomers) has been taken with monoamine oxidase inhibitors like tranylcypromine.

Pharmacology

Pharmacodynamics

Modafinil's precise mechanism of action in narcolepsy and other sleep disorders remains incompletely understood. Nevertheless, in animals and in humans modafinil acts primarily as an atypical dopamine transporter (DAT) inhibitor or dopamine reuptake inhibitor (DRI), producing a modest increase in extracellular dopamine in cortical and striatal brain regions without inducing the rapid dopamine signaling characteristic of classical stimulants such as amphetamine or cocaine.

This modest dopaminergic effect is accompanied by broader downstream activation of arousal-related neurotransmitter systems. Modafinil increases noradrenergic tone in wakefulness-promoting nuclei and indirectly engages hypothalamic orexin and histamine pathways, which together help stabilize the sleep–wake regulatory network and support sustained alertness. Although modafinil interacts with multiple neurotransmitter systems, its exact mode of action at the molecular level remains uncertain.

At the level of neural circuits, modafinil enhances glutamatergic excitatory transmission and reduces GABAergic inhibitory output within cortical and thalamic pathways, shifting network activity toward excitation and cortical activation while exerting minimal direct effects on classical monoamine receptors. These actions, including weak DAT inhibition combined with secondary catecholaminergic, orexinergic, glutamatergic, and GABAergic modulation, are thought to underlie modafinil's ability to promote wakefulness and cognitive function with a lower risk of euphoria and abuse than traditional amphetamine-like psychostimulants.

From laboratory research, modafinil has little to no affinity for serotonin or norepinephrine transporters and does not directly interact with these systems. However, studies have shown that elevated concentrations of norepinephrine and serotonin can occur as an indirect effect following modafinil administration due to increased extracellular dopamine activity. Unlike traditional psychostimulant drugs, such as cocaine or amphetamine, modafinil shows low potential for causing euphoria due to differences in how it interacts with dopamine transporters at a cellular level.

In addition to its influence on dopaminergic pathways, modafinil may impact other neurotransmitter systems, such as orexin (hypocretin) and histamine. Orexinergic and histaminergic neurons are involved in promoting wakefulness and regulating arousal states. Modafinil may increase signaling within hypothalamic orexin and histamine pathways, potentially contributing to its wake-promoting effects. In animal models, modafinil-induced increases in hypothalamic histamine release require intact orexinergic neurons.

The wake-promoting effects of modafinil do not appear to depend on the orexin system. Modafinil promotes wakefulness in narcoleptic dogs with non-functional orexin 2 receptors and in humans with type 1 narcolepsy, which is characterized by a marked loss of orexin-producing neurons. In contrast, the wake-promoting effects of modafinil are abolished in dopamine transporter knockout mice. The effects of modafinil on histamine, orexin, and other non-catecholaminergic systems may be secondary to its catecholaminergic effects.

Pharmacokinetics

Absorption

Modafinil is readily absorbed with oral administration. The oral bioavailability of modafinil is unknown. No value is established because modafinil is water-insoluble and cannot be administered intravenously. However, based on excretion studies, at least 40 to 65% of a dose of modafinil is absorbed. The pharmacokinetics of modafinil are linear or dose-proportional over a range of 200 to 800 mg orally.

The time to peak levels of modafinil is typically 2 to 4 hours. Food slightly slows the absorption of modafinil, by 0.5 to 1 hour, but does not affect the total area under the curve (AUC). Modafinil reached steady-state levels after 2 to 4 days of once-daily administration. There is 1.5-fold accumulation of modafinil with continuous administration.

Modafinil and armodafinil show similar peak levels and times to peak levels in directly comparative studies. Due to armodafinil having a longer elimination half-life than esmodafinil however, armodafinil constitutes 90% of modafinil levels at steady state with modafinil therapy.

Distribution

The apparent volume of distribution of modafinil is 0.326 to 0.8 L/kg body weight. The plasma protein binding of modafinil is approximately 60%. It is mostly (90%) bound to albumin. Both armodafinil and esmodafinil are substrates of P-glycoprotein, but the clinical significance of this is unknown.

Metabolism

Modafinil is metabolized mainly in the liver. It is metabolized mainly via amide hydrolysis into modafinil acid by esterases and/or amidases. In addition, modafinil is metabolized to a lesser extent by sulfoxidation via cytochrome P450 CYP3A4 and CYP3A5 into modafinil sulfone. The drug is also metabolized via aromatic ring hydroxylation and by subsequent conjugation via glucuronidation.

The two major circulating metabolites of modafinil are modafinil acid and modafinil sulfone. Both of these metabolites have been described as inactive, and neither appears to contribute to the wakefulness-promoting effects of modafinil. However, modafinil sulfone does appear to possess anticonvulsant effects, a property that it shares with modafinil.

Elimination

Modafinil is eliminated 90% via metabolism and 10% via renal excretion. Modafinil, given as a single dose in radiolabeled form, is excreted 80% in urine and 1% in feces by 11 days post-administration. Urinary recovery as the major metabolite modafinil acid has been found to be 35 to 51% of a dose. Less than 10% of modafinil is excreted unchanged in urine.

The elimination half-life of modafinil is in the range of 12 to 15 hours There is individual variation in this parameter depending on sex, cytochrome P450 genotypes, liver function, and renal function.

The individual enantiomers of modafinil, armodafinil and esmodafinil, have substantially different pharmacokinetics due to differing elimination profiles. Both armodafinil and esmodafinil are eliminated in a monophasic manner. However, armodafinil has a half-life of 10 to 17 hours, while esmodafinil has a half-life of 3 to 5 hours (3–4 times shorter). Consequently, modafinil has a biphasic elimination profile, with esmodafinil being eliminated much more rapidly than armodafinil. Armodafinil and modafinil have shown virtually identical elimination half-lives of approximately 12 to 16 hours in directly comparative studies. However, due to the biphasic elimination profile of modafinil, armodafinil shows higher levels than modafinil from 4 to 6 hours after administration and about 40% higher area-under-the-curve (AUC) levels than modafinil. Moreover, armodafinil showed 42% lower peak-to-trough variation than modafinil with once-daily administration at steady state. Because of the preceding, modafinil has a shorter duration and less stable levels than armodafinil.

Specific populations

Modafinil exhibits sex-specific pharmacokinetic differences. It demonstrates higher bioavailability in women compared to men. The mean C_max is higher in women than in men, 5.2 mg/L vs. 4.2 mg/L (p < 0.05), following a single 200 mg oral dose of modafinil. This difference persists even after adjusting for body weight (0.88 ml/min/kg vs. 0.72 ml/min/kg). The clearance of modafinil is 30% higher in men than in women, and plasma concentrations after a single dose are significantly higher in women than in men. These sex-specific pharmacokinetic differences may have implications for the efficacy and safety of modafinil.

Chemistry

Enantiomers

Modafinil is a racemic mixture of two enantiomers, armodafinil ((R)-modafinil) and esmodafinil ((S)-modafinil).

Detection in body fluids

Modafinil and/or its major metabolite, modafinil acid, may be quantified in Plasma, serum, or urine to monitor dosage in those receiving modafinil therapeutically, to confirm a diagnosis of poisoning in hospitalized patients, or to assist in the forensic investigation of a vehicular traffic violation. Instrumental techniques involving gas or liquid chromatography are usually employed for these purposes. In 2011, modafinil was not tested for by common drug screens (except for anti-doping screens) and is unlikely to cause false positives for other chemically unrelated drugs such as substituted amphetamines.

Reagent testing can screen for the presence of modafinil in samples.

Structural analogues

Many derivatives and structural analogs of modafinil have been synthesized. Examples include adrafinil, CE-123, fladrafinil (CRL-40941; fluorafinil), flmodafinil (CRL-40940; bisfluoromodafinil, lauflumide), RDS03-94, JJC8-088, modafiendz and modafinil sulfone.

History

Modafinil was developed in France by neurophysiology professor Michel Jouvet and Lafon Laboratories in the 1970s. Modafinil is the primary metabolite of adrafinil, an earlier compound in the benzhydryl sulfinyl series. Modafinil has been prescribed in France since 1994 under the name Modiodal, and in the United States since 1998 as Provigil.

The US Food and Drug Administration approved modafinil in 1998 for narcolepsy treatment, and later for shift work sleep disorder and obstructive sleep apnea in 2003. It was approved in the UK in December 2002. In the United States, modafinil is marketed by Cephalon, a biopharmaceutical company acquired by Teva Pharmaceutical Industries in 2011, who acquired the rights from Lafon and purchased the company in 2001.

Cephalon introduced armodafinil, the (R)-enantiomer of modafinil, in the United States in 2007. Generic versions of modafinil became available in the US in 2012 after extensive patent litigation.

Society and culture

Modafinil's use varies by region. In the US, it is approved for adult narcolepsy, shift work sleep disorder, and obstructive sleep apnea, but not for children. In the UK and the EU, since 2014, it is approved solely for narcolepsy, including in children (pediatric narcolepsy), with its use for other conditions restricted by the European Medicines Agency. Modafinil is not approved for use by children in multiple jurisdictions.

Legal status

In 2008, Cephalon, the manufacturer of Provigil, pleaded guilty to a federal criminal charge related to its promotion of off-label uses of Provigil and two other drugs, paying $425 million in fines and settlements.

Brand names

Modafinil is marketed under numerous brand names worldwide.

Economics

Concerns have been raised about the growing use of modafinil as a "smart drug" or cognitive enhancer among healthy individuals who use it with the aim to improve concentration and memory. In 2003, modafinil sales rose sharply amid concern that it was being used as a stimulant by people seeking an extra edge. The cost of modafinil has decreased substantially since generic versions became available in the US in 2012; retail prices for generic modafinil (30 tablets of 200 mg) range from approximately $20 to $45 with discount programs, compared to over $120 per month for brand-name Provigil in 2004.

Global sales figures for modafinil have not been publicly disclosed. Modafinil sold under the brand name Provigil accounted for over 40% of Cephalon's global turnover for several years, according to data published in 2020.

Patent protection and litigation

The original patent, U.S. patent 4,927,855, was granted to Laboratoire L. Lafon in 1990, covering the chemical compound of modafinil. This patent expired in 2010. In 1994, Cephalon filed a patent for modafinil in the form of particles of a defined size, represented by U.S. patent 5,618,845, which expired in 2015.

Following the nearing expiration of marketing rights in 2002, generic manufacturers, including Mylan and Teva, applied for US Food and Drug Administration approval to market a generic form of modafinil, leading to legal challenges by Cephalon regarding the particle size patent. The patent RE 37,516 was declared invalid and unenforceable in 2011.

In addition, Cephalon entered agreements with several generic drug manufacturers to delay the sale of generic modafinil in the US. These agreements were subject to legal scrutiny and antitrust investigations, culminating in a ruling by the Court of Appeals in 2016, which found that the settlements did not violate antitrust laws.

Social views

The use of modafinil as a supposed cognitive enhancer may be considered as cheating, unnatural, or risky. The University of Sussex explained that it is a prescription drug and the decision should be made by the doctor on whether to prescribe modafinil to a student. As a matter of bioethics, the US President's Council on Bioethics argued that excellence achieved through the use of drugs like modafinil is "cheap" as it obviates the need for hard work and study, and is not fully authentic because the excellence is partly attributable to the drug, not the individual. Alternately, people in Wall Street trading may consider it a tool for a competitive edge in a high-intensity environment. Due to such varying views, modafinil users for narcolepsy may cope with stigma by hiding, denying, or justifying their use, or by seeking support from others who share their views or experiences.

Research

Psychiatric conditions

Major depressive disorder

Modafinil has been studied as an adjunctive treatment for major depressive disorder. While some individual trials have reported benefits, systematic reviews and meta-analyses have found the evidence limited, the quality of evidence low, and the results inconclusive; modafinil did not significantly improve depression in network meta-analysis, though there was some evidence for reduced fatigue and sleepiness.

Substance dependence

Modafinil has been studied as a potential treatment for stimulant dependence and cocaine addiction, but clinical trials have failed to show that it helps reduce drug use or maintain abstinence; 2024 reviews found it ineffective for amphetamine-type stimulant use disorder, methamphetamine use disorder, and cocaine dependence.

Schizophrenia

Modafinil and armodafinil were studied as a complement to antipsychotic medications in the treatment of schizophrenia. They showed no effect on positive symptoms or cognitive performance. A 2015 meta-analysis found that modafinil and armodafinil may slightly reduce negative symptoms in people with acute schizophrenia, though they do not appear useful for people with stable schizophrenia who have prominent negative symptoms (such as reduced motivation or social withdrawal). Among medications demonstrated to be effective for reducing negative symptoms in combination with antipsychotics, modafinil, and armodafinil are among the smallest effect sizes.

Motivational disorders

In animal studies, modafinil has been found to reverse tetrabenazine-induced motivational deficits, suggesting potential pro-motivational effects. Novel modafinil analogs are being developed as potential treatments for motivational disorders in humans.

Cognitive enhancement

Systematic reviews have found limited evidence for modafinil as a cognitive enhancer in healthy, non-sleep-deprived individuals. A 2019 review found small enhancements in attention, executive functions, and learning, but impairments in divergent creative thinking in some studies. A 2020 review reported only a modest effect on memory updating, concluding there is insufficient evidence to support the perception that modafinil is a useful cognitive enhancer.

Postural orthostatic tachycardia syndrome

Modafinil has been studied and used in the treatment of postural orthostatic tachycardia syndrome (POTS).

Other conditions

Modafinil has been investigated for several other conditions with inconclusive or preliminary results. Preliminary research is examining modafinil for excessive daytime sleepiness in myotonic dystrophy, though it is not approved for this use and results are debated. Modafinil has also been studied for disorders of consciousness, but observational reports have produced mixed results.